Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The immune checkpoints Cytotoxic T lymphocyte antigen‐4 and Lymphocyte activation gene‐3 expression is up‐regulated in acute myeloid leukemia
Sara M. Radwan, Nooran S. Elleboudy, Nermeen Nabih, et al.
HLA (2020) Vol. 96, Iss. 1, pp. 3-12
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Letong Cai, Yuchen Li, Jiaxiong Tan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 133
Catch me if you can: how AML and its niche escape immunotherapy
Sarah Tettamanti, Alice Pievani, Andrea Biondi, et al.
Leukemia (2021) Vol. 36, Iss. 1, pp. 13-22
Open Access | Times Cited: 131
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy
Tatjana Sauerer, Giuliano Filippini Velázquez, Christoph Schmid
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 37
The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways
Maryam Bakhtiyari, Mahsa Liaghat, Fatemeh Aziziyan, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 31
Novel immune checkpoint targets: A promising therapy for cancer treatments
Mohsina Patwekar, Nouroz Sehar, Faheem Patwekar, et al.
International Immunopharmacology (2023) Vol. 126, pp. 111186-111186
Closed Access | Times Cited: 23
Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes
Amany M. Kamal, Eman F. Wasfey, Wesam Reda Elghamry, et al.
Clinical Biochemistry (2021) Vol. 96, pp. 13-18
Closed Access | Times Cited: 31
A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia
Başak Aru, Cemil Pehlivanoğlu, Zeynep Dal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Wenyue Sun, Shunfeng Hu, Xin Wang
Cancer Communications (2024) Vol. 44, Iss. 9, pp. 1071-1097
Open Access | Times Cited: 4
Bone marrow immune cells and drug resistance in acute myeloid leukemia
Miao Zhang, You Yang, Jing Liu, et al.
Experimental Biology and Medicine (2025) Vol. 250
Open Access
The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis
Dai-Hong Xie, Siqi Li, Kai Sun, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 5
Open Access
Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias
Julian Swatler, Laura Turos-Korgul, Ewa Kozłowska, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1203-1203
Open Access | Times Cited: 23
Immunotherapy in leukaemia
Xingmei Mu, Chumao Chen, Loujie Dong, et al.
Acta Biochimica et Biophysica Sinica (2023) Vol. 55, Iss. 6, pp. 974-987
Open Access | Times Cited: 8
Immunotherapy in Acute Myeloid Leukemia: A Literature Review of Emerging Strategies
Luca Guarnera, Carlos Bravo‐Pérez, Valeria Visconte
Bioengineering (2023) Vol. 10, Iss. 10, pp. 1228-1228
Open Access | Times Cited: 8
Expression of immune check point gene TIM‑3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome
Amany M. Kamal, Nermeen Nabih, Nooran S. Elleboudy, et al.
Oncology Letters (2021) Vol. 21, Iss. 4
Open Access | Times Cited: 18
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies
Mohammad Reza Sadeghi, Atefeh Khodakarami, Armin Ahmadi, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 12, pp. 1057-1071
Closed Access | Times Cited: 11
Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Georgios Petros Barakos, Eleftheria Hatzimichael
Diseases (2022) Vol. 10, Iss. 2, pp. 33-33
Open Access | Times Cited: 9
Effects of Combinatory In Vitro Treatment with Immune Checkpoint Inhibitors and Cytarabine on the Anti-Cancer Immune Microenvironment in De Novo AML Patients
Łukasz Bołkuń, Aleksandra Starosz, Anna Krętowska-Grunwald, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 462-462
Open Access | Times Cited: 1
Construction of an immune-related prognostic signature and lncRNA–miRNA–mRNA ceRNA network in acute myeloid leukemia
Ling Qin, Boya Li, Shijie Wang, et al.
Journal of Leukocyte Biology (2024) Vol. 116, Iss. 1, pp. 146-165
Open Access | Times Cited: 1
Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy
Johanna Rausch, Evelyn Ullrich, Michael W.M. Kühn
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Serum levels of FAK and some of its effectors in adult AML: correlation with prognostic factors and survival
Mona G. El-Sisi, Sara M. Radwan, Alia Saeed, et al.
Molecular and Cellular Biochemistry (2021) Vol. 476, Iss. 5, pp. 1949-1963
Closed Access | Times Cited: 7
The Emerging Role of Lymphocyte Activation Gene 3 in the Cancer Immunotherapy
Xue Cui, Min Peng, Honglei Chen
ONCOLOGIE (2022) Vol. 24, Iss. 4, pp. 665-678
Open Access | Times Cited: 4
The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients
Sara M. Radwan, Nooran S. Elleboudy, Nermeen Nabih, et al.
Egyptian Journal of Medical Human Genetics (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
David Spillane, Sarit Assouline
Expert Review of Hematology (2023) Vol. 16, Iss. 11, pp. 819-834
Closed Access | Times Cited: 1
Association of Polymorphisms in PD-1 and LAG-3 Genes with Acute Myeloid Leukemia
Lamjed Mansour, Mashael Alqahtani, Ali Aljuaimlani, et al.
Medicina (2024) Vol. 60, Iss. 5, pp. 721-721
Open Access
Expression of immune checkpoint molecules in Iraqi acute myeloid leukemia patients
HassnienSamir Al-Hashemi, SabahA. Hameid A. Rahman, ZeyadAhmed Shabeeb
Iraqi Journal of Hematology (2021) Vol. 10, Iss. 1, pp. 1-1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top